| Gene Symbol | STX17 |
| Full Name | Syntaxin 17 |
| Chromosome | 9q31.3 |
| Protein Type | Structural Protein |
| Target Class | Structural Protein |
| Function | STX17-targeting drugs would enhance or modulate autophagosome-lysosome fusion by facilitating SNARE complex assembly, thereby improving autophagic clearance of misfolded proteins and damaged organe... |
| Mechanism of Action | STX17-targeting drugs would enhance or modulate autophagosome-lysosome fusion by facilitating SNARE complex assembly, thereby improving autophagic clearance of misfolded proteins and damaged organelles. This mechanism is particularly relevant for neurodegenerative diseases characterized by protein aggregation. |
| Druggability | Medium (0.46) |
| Clinical Stage | Phase II |
| Pathways | Apoptosis, Autophagy, Cell Cycle, Lysosomal Degradation, Mitophagy |
| UniProt ID | Q9NYQ6 |
| NCBI Gene ID | 55276 |
| Ensembl ID | ENSG00000143891 |
| OMIM | 612598 |
| GeneCards | STX17 |
| Human Protein Atlas | STX17 |
| Associated Diseases | ALS, Aging, Alzheimer's disease, Cardiac, Ftd |
| Known Drugs/Compounds | donanemab, lecanemab, rapamycin |
| Interactions | ATG5, SQSTM1, NOS3, STING1, GLP1R, SREBF1 |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | Autophagosome Maturation Checkpoint Control |
| KG Connections | 1121 knowledge graph edges |
| Databases | GeneCardsHPASTRING |